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Radiotherapy (RT) primarily aims to locally destroy the tumor via the induction of DNA 
damage in the tumor cells. However, the so-called abscopal, namely systemic and 
immune–mediated, effects of RT move over more and more in the focus of scientists and 
clinicians since combinations of local irradiation with immune therapy have been demon-
strated to induce anti-tumor immunity. We here summarize changes of the phenotype 
and microenvironment of tumor cells after exposure to irradiation, chemotherapeutic 
agents, and immune modulating agents rendering the tumor more immunogenic. The 
impact of therapy-modified tumor cells and damage-associated molecular patterns on 
local and systemic control of the primary tumor, recurrent tumors, and metastases will 
be outlined. Finally, clinical studies affirming the bench-side findings of interactions and 
synergies of radiation therapy and immunotherapy will be discussed. Focus is set on 
combination of radio(chemo)therapy (RCT) with immune checkpoint inhibitors, growth 
factor inhibitors, and chimeric antigen receptor T-cell therapy. Well-deliberated combina-
tion of RCT with selected immune therapies and growth factor inhibitors bear the great 
potential to further improve anti-cancer therapies.
Keywords: radiotherapy, abscopal effect, immune therapy, checkpoint inhibitors, PD-L1, DAMP, eGFR, anti-
tumor immunity
Radiotherapy (RT) is an integral part of multimodal cancer treatments (1). Besides its local mode 
of action on tumor cell DNA, it can induce systemic and immune-mediated anti-tumor responses, 
especially in combination with additional immune activation (2). The current review focuses on 
induction of immunogenic cancer cell death by RT and on interactions of RT with selected immune 
therapies to induce a long-lasting, local, and systemic tumor control.
According to the WHO, cancer incidences are expected to increase by over 50% until 2020 (3). 
With this in mind, the clinical management of treatment modalities is a big challenge for scien-
tists and clinicians alike. Consequently, improving the understanding of cellular and molecular 
processes occurring in the patients during therapies will help to optimize the design of clinical 
trials and ultimately that of patient treatment as well. Common therapy options comprise surgery, 
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RT, chemotherapy (CT), immunotherapy (IT), targeted therapy, 
hyperthermia (HT), and hormonal therapy, all of which are either 
administered as a stand-alone therapy or in various combina-
tions. Out of all these options, over 50% of all cancer patients 
receive RT (4).
RT-induced DNA Damage
The clear-cut aim of RT is the deposition of a maximal dose of 
ionizing radiation (IR) in the tumor while simultaneously spar-
ing healthy tissue. A significant amount of damage within the 
malignant cells ultimately leads to the loss of clonogenicity, the 
induction of cell death and finally in the reduction of tumor size. 
This is achieved either directly or indirectly: radiation induces 
DNA lesions and creates highly reactive radicals that then also 
damage DNA. The accumulation of DNA lesions can jeopardize 
the genomic stability of the cell, especially when the DNA damage 
response (DDR) system is impaired. Individuals with germ-line 
mutations in DDR genes show a higher predisposition for cancer. 
Errors in this highly regulated process of DDR can result in accu-
mulation of genomic mutations and malignant transformation. 
On the other hand, DDR also acts as a negative saboteur to resist 
CT and RT (5). Forms of IR-induced DNA damage that endanger 
chromatin integrity are single-strand breaks (SSBs) and double-
strand breaks (DSBs) of the DNA, whereas SSBs (~1000/Gy) (6) 
are way more frequent than DSBs (~40–50/Gy) (7). However, 
the time to repair DSBs takes much longer. Cells have developed 
several DNA repair pathways, such as homologous recombina-
tion (HR), non-homologous end-joining (NHEJ), nucleotide 
excision repair (NER), and base excision repair (BER) as well as 
mismatch repair (MMR) dependent on size and modality of the 
DNA damage (for further interest on this topic refer to Ref. (8)). 
Still, if the cell is no longer able to compensate the damage, cell 
death is the final consequence.
RT-induced Cell Death
Mitotic catastrophe, apoptosis, autophagy, and senescence have 
been the most prominent observed forms of cell death induced by 
RT (9). Within the last years, it has become evident that tumor cell 
necrosis can be induced in a programed manner besides occur-
ring through a more or less unregulated process (10).
Apoptosis
Apoptosis is a programed cell suicide and the best characterized 
form of cell death. It is of particular importance during develop-
ment and aging to maintain a homeostatic balance in tissues. A 
dysfunctional regulation can result in autoimmune diseases, viral 
infections, or cancer. In cancer therapy, apoptosis can be induced 
in tumor cells by the use of IR and/or cytotoxic drugs (11). In 
general, two main pathways exist: the intrinsic mitochondrial 
pathway is mainly regulated by proteins of the B-cell lymphoma-2 
(Bcl-2) family, which includes pro- and anti-apoptotic proteins, 
whereas the extrinsic pathway is induced by cell death receptors 
on the cell surface. In early stages of apoptosis, the cell maintains 
its organelle integrity and the cell membrane remains intact. 
In later stages, various morphological changes of the cell are 
visible: cell shrinkage, chromatin condensation, DNA fragmen-
tation, membrane blebbing, and formation of apoptotic bodies 
(12). Under normal conditions, apoptotic cells are engulfed 
by neighboring “non-professional” phagocytic cells, such as 
mesenchymal and epithelial cells (13). However, if the number 
of apoptotic cells exceeds a certain level, professional phagocytes 
are attracted to the site by the so-called “find me” signals that 
are released by dying cells (14, 15). These signals include factors 
such as nucleotides, proteins, and phospholipids (14, 15). The 
uptake of apoptotic cells by other cells is facilitated by changes 
within the outer membrane of the dying cell, the so-called “eat 
me” signals. One of the most prominent of these signals is phos-
phatidylserine (PS) that, under normal conditions, is located on 
the inner plasma membrane leaflet. During apoptosis, however, 
it translocates to the outer side of the lipid layer where it can 
be recognized by adaptor proteins and specific PS receptors 
on phagocytes (16). The detection and ingestion of apoptotic 
material by macrophages predominantly induces the release of 
anti-inflammatory cytokines while simultaneously inhibiting 
the production of pro-inflammatory cytokines (Figure  1). By 
contrast, the uptake of apoptotic cells by immature dendritic 
cells (DCs) inhibits their maturation and induces tolerance (17). 
Therefore, apoptosis subserves several pro-tumor functions 
(18). Strategies have emerged to increase the immunogenicity of 
apoptotic cells by blocking their clearance by macrophages with 
the PS-binding protein AnnexinA5 (AnxA5) (19). Pre-clinical 
experiments revealed a long-lasting immune memory against 
tumor cells and a delayed tumor growth mediated by AnxA5 
when given in combination with IR (20).
Nevertheless, apoptosis often plays a subordinate role in solid 
tumors, as tumor cells acquire resistance to apoptosis through 
several mechanisms; e.g., the tumor suppressor gene p53 is 
mutated in more than 50% of human malignancies (9). Other 
resistance mechanisms are overexpression of anti-apoptotic pro-
teins, inactivation of pro-apoptotic genes, as well as interference 
with the death cell receptor and perforin/granzyme pathway (21).
Necrosis
In contrast to apoptosis, necrosis has often been defined as an 
uncontrolled or pathological cell death, which can be induced by 
extreme cellular stress such as trauma, infections, detergents, toxic 
agents, or heat. Morphologically, it is characterized by cellular 
swelling, rupture of the plasma membrane, and loss of intracellu-
lar content (22). It is considered to be a pro-inflammatory form of 
cell death due to its release of damage-associated molecular pat-
terns (DAMPs) such as heat shock proteins (HSP), high mobility 
group box 1 (HMGB1), nucleotides, or uric acid leading to an 
activation of both, the innate and the adaptive immune system 
(22, 23) (Figure 1). In the last few years, it has become clear that 
there is a second form of necrosis, the so-called necroptosis, 
which is dependent on the receptor-interacting protein (RIP) 
kinases RIP1 and RIP3 (24, 25). It can be induced by factors 
such as tumor necrosis factor (TNF), Fas Ligand, or TNF-related 
apoptosis-inducing ligand (TRAIL) and utilizes the same initial 
signaling cascade as cell death receptor-induced apoptosis (25, 
26). In addition, necroptosis can be manipulated by inhibitors 
such as Necrostatin 1, which blocks RIP1 kinase activity (27).
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Therapeutic applications of RT and CT, either as stand-alone 
therapies or in combination with targeted therapies or IT, should 
stimulate local and systemic tumor control through the induction 
of immunogenic forms of cell death, which in turn can initiate 
persistent anti-tumor immune response. Particularly, both forms 
of necrosis are considered to be more immunogenic than the 
apoptosis and can therefore be useful tools to shift the tumor 
microenvironment toward an immunostimulatory rather than 
an immunosuppressive one (28) (Figure 1).
impact of the Fractionation of Radiation 
on Anti-Tumor Responses
It has become obvious that radiation-induced non-(DNA) tar-
geted, systemic effects are immune mediated and therefore also in 
part dependent on the primary cell death induction in the irradi-
ated area (29, 30). With the emerging development of accelerators 
that has made it possible to deliver precisely higher single doses 
into the tumor area, one should focus on the immunological con-
sequences of the different forms of radiation treatment as current 
pre-clinical data are not conclusive (2). RT can be administered 
in conventional fractionation schemes (1.8–2.2  Gy/fraction; 1 
fraction/day, 5  days/week for 3–7  weeks), hyperfractionation 
(0.5–2.2  Gy/fraction, two fractions/day, 2–5 fractions/week for 
2–4 weeks) or hypofractionation (3–20 Gy/fraction, 1 fraction/
FiGURe 1 | Noxious agents may induce non-immunogenic and immunogenic cell death. Stressed cells can either undergo a non-immunogenic cell death 
resulting in their anti-inflammatory clearance. The stress-resulting damage might, however, also foster immune reactions. Immunogenic forms of cell death, main 
characteristics of which are displayed in the figure, stimulate the immune system especially through the release of damage associated molecular patterns (DAMPs). 
Dendritic cells mature, are activated and initiate a cytotoxic T-cell response against the tumor cells.
day) (31) using various therapeutic systems, including stereotac-
tic radiosurgery. In the latter, the external radiation procedure 
utilizes multiple convergent beams to deliver high single doses to 
a small volume while sparing adjacent normal tissue. Currently, 
three different main modalities, namely LINAC, Gamma Knife, 
and protons are used for stereotactic radiosurgery, especially for 
the treatment of brain tumors with limited size that cannot be 
removed surgically (32).
Pre-clinically, Rubner et al. showed that fractionated RT is 
the main stimulus for cell death induction and HSP70 release 
in p53 mutated and O6-methylguanine methyltransferase, 
a DNA repair protein, negative glioblastoma cell lines (33). 
Tsai et  al. investigated whether single high dose vs. multiple 
small doses with a total dose of 10  Gy differentially alters 
gene expression. They found out, amongst others, that there 
are significant differences in the gene response depending on 
the fractionation of radiation: 10  Gy delivered in fractions 
lead to a more stable induction of genes (34). Multhoff et  al. 
hypothesized that conventional fraction schemes over several 
weeks are thought to be rather negative for radiation-induced 
anti-tumor immune responses as tumor-infiltrating immune 
lymphocytes might be killed by the repeating irradiation (35). 
Dewan et al. investigated the effects of RT with immune modu-
latory anti-CTLA4-antibodies on induction of anti-tumor 
immune responses. In his model system 3 × 8 Gy was superior 
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to that of 5 × 6 Gy in induction of a T-cell-dependent abscopal 
anti-tumor effect (36). This indicates that a higher single dose 
applied in hypofractionated schemes is advantageous to boost 
the immune system.
While it has been known that cellular effects of stereotactic 
radiosurgery include the induction of necrotic cell death and 
endothelial proliferation with luminal narrowing and thrombo-
sis, Witham et al. used a rat glioma model to investigate whether 
gamma knife radiosurgery also induces apoptosis. They found 
tumor apoptosis to be statistically higher in treated animals at 
6, 24, and 48 h after radiosurgery (37). Taken together, all these 
data show that more pre-clinical and clinical research are needed 
to define the best single dose and the respective fractionation 
scheme for induction of immunogenic cancer cell death and 
consecutive anti-tumor immunity.
induction of Anti-Tumor immunity
The Role of DCs in Anti-Tumor immune 
Response
The activation of the immune system is vital to promote a long-
lasting anti-tumor response. An essential asset for creating a 
potent anti-tumor immunity is the activation of DCs and con-
secutively cytotoxic CD8+ T lymphocytes (CTL) alongside with 
CD4+ T lymphocytes. Being the most efficient antigen-presenting 
cells, DCs play an important role in the initiation of the adaptive 
immunity. However, before DCs can stimulate any other cell type, 
they have to be activated properly. Such activating signals are not 
only foreign substances or infected cells, but can also be derived 
endogenously from stressed cells or cells dying by necrosis (38), 
as it is the case in tumor therapy. Immature DCs can then acquire 
and process tumor material, migrate to lymph nodes, and present 
or cross-present peptides of tumor-associated antigens (TAA) 
to naïve T cells in a MHC-II- or MHC-I-dependent manner, 
respectively (39). Aside from stimulating T-cell responses via the 
expression of co-stimulatory molecules such as CD80, CD86, as 
well as members of the TNF family (e.g., CD40, CD137 (4-1BB)
L, OX40L) that can interact with the corresponding receptors on 
T cells, mature DCs secrete a wide range of pro-inflammatory 
cytokines (40). They therefore favor T-cell activation, survival, 
and differentiation and thus specific anti-tumor immune 
responses (41, 42).
DAMPs as Mediators of DC Activation
Other important factors for DC activation and maturation are 
secreted or exposed danger signals by dying cells, the so-called 
DAMPs (43). The surface exposure or release of DAMPs can 
be induced by IR or certain immunogenic chemotherapeutics, 
which are therefore capable of initiating a solid anti-tumor 
immune response (44). One of these signals is the early pre-
apoptotic exposure of the endoplasmic reticulum (ER) protein 
calreticulin (CRT) on the plasma membrane surface. This can be 
induced by IR or substrates such as anthracyclines or oxaliplatin 
and triggers the uptake of tumor cells by DCs. In the presence of 
later DAMPs, such as HMGB1, the internalized tumor antigens 
get processed and cross-presented finally resulting in stimulation 
of tumor-specific CTLs (45, 46).
High mobility group box 1 is a chromatin-associated nuclear 
protein functioning as a DAMP when being expressed extracel-
lularly. It is passively released by necrotic or damaged cells and 
secreted by immune cells such as macrophages, natural killer 
(NK) cells, neutrophils, mature DCs, and T cells and binds with 
high affinity to the receptor for advanced glycation end-products 
(RAGE) as well as the toll-like receptors (TLR)2, TLR4, and TLR9 
(47). Its release from tumor cells can be induced by various stimuli, 
such as RT (33) and especially after combinatory treatment of RT 
with further immune stimulation, e.g., HT (48). Chemotherapeutic 
agents like temozolomide, melphalan, and paclitaxel might also 
foster its release (49, 50). HMGB1 interaction with a functional 
TLR4 on DCs is required for an efficient cross-presentation of 
tumor-antigens to T cells (51) and the priming of a tumor-specific 
T-cell response. The importance of TLR4 activation via danger 
signals can be seen in patients suffering from breast cancer, head 
and neck squamous cell carcinomas (HNSCC), or colorectal can-
cer carrying a loss of function single-nucleotide polymorphism 
(SNP) in the Tlr-4 locus that have a predicted worsened outcome 
after immunogenic CT with anthracyclines or oxaliplatin (51, 
52). However, HMGB1 also shows pro-tumorigenic proper-
ties. Thus, overexpression of HMGB1 and its receptor RAGE is 
observed in several cancers and is associated with tumor growth 
and metastasis (53). A possible explanation for the contradictory 
effects of HMGB1 might be a change of its redox state. Reducible 
HMGB1 binds to RAGE but not to TLR4 and promotes resistance 
to melphalan, paclitaxel, doxorubicin, and oxaliplatin, oxidized 
HMGB1, on the other hand, increases the cytotoxicity of these 
agents (54). One might speculate that RT-induced mitochondrial 
ROS production contributes to oxidation of HMGB1 and thereby 
to immunogenicity (55).
Another example for a DAMP that can be either passively 
released or actively secreted by dying or stressed cells is adenosine-
5-triphosphate (ATP). It acts on purinergic P2RX7 receptors on 
DCs that in turn activate the NLRP3/ASC/caspase-1 inflamma-
some, finally resulting in the secretion of interleukin (IL-) IL-18 
and IL-1β (56). IL-1β is required for efficient priming of CD4+ T 
cells and interferone-γ (IFN-γ) producing tumor antigen-specific 
CD8+ CTLs (57) and therefore for the generation of an anti-tumor 
immune response. Furthermore, ATP release from tumor cells also 
contributes to tumor growth and modulates immunosuppressive 
properties of myeloid-derived suppressor cells (MDSC) via a 
P2 × 7 receptor dependent mechanism (58).
HSP70 released from stressed cancer cells can also serve as 
a danger signal. HSPs are among the most abundant proteins 
in cells. Intracellular HSPs function as chaperons ensuring the 
correct folding or degradation of misfolded proteins. Under 
stress-induced conditions such as oxidative stress, HT, irradia-
tion, or chemotherapeutics, intracellularly located HSPs are over-
expressed and can be translocated to the plasma membrane or 
be released into the extracellular compartment, thereby acting as 
danger signals. In this way, HSP70 and HSP90 in particular play 
a dual role in cancer. Intracellularly, they protect tumor cells from 
programed cell death by interfering with apoptotic processes 
(59). However, if they are bound to the plasma membrane or 
released they contribute to the activation of the innate and adap-
tive immune system (60, 61). HSP70 promotes DC maturation as 
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well as NK cell migration, activation, and cytolytic activity. Also 
HSP70 is thought to be associated with tumor antigens trigger-
ing their cross-presentation via MHC-I on DCs and stimulating 
a CD8+ T-cell response (62). Relevance of exposed HSP70 as a 
tumor-specific recognition structure is given by the group of 
Multhoff et al. who found that HSP70 is expressed on the plasma 
membrane of 40 (colon), 37 (gastric), 43 (lower rectal), and 42% 
(squamous cell) tumor specimens, but never on healthy cells. 
However, during the investigation, it became clear that the tumor 
entity is of major importance for clinical outcome. They therefore 
suggest the usage of HSP70 as a potential prognostic marker for 
overall survival (OS) (63).
To sum up, danger signals such as CRT, HMGB1, ATP, and 
HSPs are inducible by several chemotherapeutic drugs or irra-
diation. They play important roles in the priming of anti-tumor 
immune responses, but, depending on their location, concentra-
tion, and redox state, can also promote tumor development and 
progression.
Therapy-Dependent Modulation of the 
Tumor Microenvironment
Tumors have developed several molecular and cellular mecha-
nisms to evade immune surveillance. These strategies include the 
secretion of immunosuppressive factors such as TGF-β, IL-10, 
or indoleamine 2,3-dioxygenase (IDO) (64–68), the alteration 
of antigen-presentation (69, 70), disruption of T-cell activation 
(71), apoptosis promotion of activated T cells (72), as well as the 
recruitment of regulatory cells or in general the inhibition of 
immune cells (73–75).
However, given that the immune system provides a pos-
sible strategy to create an efficient and long-lasting anti-tumor 
response, it is necessary to find treatment strategies that overcome 
the protective immunosuppressive microenvironment created by 
the tumor. Lately, it has become clear that standard treatments, 
namely RT and CT, can already render tumors and their micro-
environment more immunogenic (76). As outlined above, RT 
and CT are able to induce both apoptotic and necrotic tumor cell 
death resulting in surface exposure and release of danger signals 
or TAAs. Aside from inducing tumor cell death, various chemo-
therapeutics, even or especially at low concentrations, stimulate, 
e.g., the expression of components of the antigen-processing 
machinery together with co-stimulatory molecules (e.g., CD40, 
CD80, CD86, MHC-II) on DCs thus promoting the stimulation 
of tumor-specific T cells, resulting in an anti-tumor immune 
response.
immunogenicity of Radiotherapy
While low doses of IR have anti-inflammatory effects (77), higher 
doses (>1 Gy) applied in tumor therapy are capable of stimulating 
the immune system in several ways: RT can enhance the expres-
sion of MHC-I on the surface of tumor cells alongside with cell 
death receptors Fas/CD95 and NKG2D ligand, thus boosting 
the recognition and killing of irradiated tumor cells through T 
cells and NK cells (78–80). IR also has the ability to induce the 
production and release of CXCL16 in tumor cells. CXCL16 is a 
chemokine binding to its receptor CXCR6 on activated T cells 
therefore enhancing their recruitment to the tumor site (81). In 
addition, it also increases IFN-γ production that alters expression 
of adhesion molecules on vasculature, chemokines, and MHC-I 
expression, thus creating a microenvironment beneficial for 
T-cell infiltration and recognition of tumor cells by CTLs (82). 
Both, fractionated, hypofractionated, and ablative regimes bear 
the potential to stimulate immune responses (83, 84). However, 
which fractionation scheme and single dose of RT is the most 
immunogenic is under current intensive investigation and dis-
cussion (15, 42).
Taking all these factors into account, it becomes clear that CT 
and RT aside from their initial purpose to stop the proliferation of 
tumor cells and kill them are useful tools to shift an immunosup-
pressive tumor microenvironment to a more beneficial immune 
stimulatory one. A detailed understanding of the molecular 
mechanisms underlying these effects is therefore essential toward 
an optimized treatment.
Systemic effects of Radiotherapy
As mentioned before, radiation, together with surgery and 
chemotherapeutics, is one of the most important tools in cancer 
treatment with the primary goal to achieve local control of tumor 
growth. Furthermore, it also enhances the tumors immunogenic-
ity through the induction of distinct tumor cell death forms and 
the release of pro-inflammatory cytokines, chemokines, as well 
as danger signals. It therefore bears the potential to induce adap-
tive and innate immune responses, resulting in systemic anti-
tumorigenic effects even outside of the field of irradiation (85). 
The phenomenon of regression of distant tumors or metastases 
outside the irradiation field is called abscopal effect of RT and its 
connection with immune events was first described by Nobler in 
1969 (86). Since abscopal sounds a bit mystic, one should rather 
term it systemic immune-mediated effects of RT nowadays. Such 
reactions have been observed in many pre-clinical studies as 
well as in clinical settings for several tumor entities, including 
melanoma, hepatocellular, renal-cell, and mammary carcinomas, 
chronic lymphocytic leukemia (CLL), or malignant lymphomas 
[for further reading, see Ref. (42, 87)].
On a cellular level, it was demonstrated that the adaptive 
immune systems contributes to these systemic reactions and that 
NK cells are also involved (88, 89). In addition, the release of danger 
signals or cytokines such as TNF-α and IFN-γ by radiation-dam-
aged tumor cells promote DC maturation and cross-presentation 
resulting in the regression of more distant tumor masses through 
activation of tumor-specific T cells (36, 88, 90).
However, in most tumor entities RT alone is not sufficient to 
induce such systemic immune reactions (89). Therefore, combi-
nation with IT might be the solution. A combined treatment of 
RT with the DC growth factor Flt-3 induced immune-mediated 
anti-tumor responses outside the irradiation field (89). Shiraishi 
et al. observed such effects after combined treatment of colon26 
adenocarcinoma-bearing Balb/c mice with fractionated RT and 
the macrophage inflammatory protein-1 alpha variant ECI301 
(88). A better local control and regression of the not irradiated 
tumor was observed by Jurgenliemk-Schulz and colleagues after 
additional rIL-2 treatment to RT in SL2 lymphoma or M8013 
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mammary carcinoma inoculated mice (91). Another approach 
is the modification of tumor cells or DCs with genetically engi-
neered viruses expressing various cytokines, including IL-2 (92, 
93), IL-12, IL-18 (94, 95), GM-CSF (96), or IFN-β (97) to enhance 
anti-tumor immunity and protect against tumor re-challenge. 
Just recently, Golden et  al. reported about immune-mediated 
systemic tumor responses when combing RT with GM-CSF for 
the treatment of patients with metastatic solid tumors (98).
A further encouraging strategy to improve the effectiveness 
of standard therapies is the usage of monoclonal antibodies 
(mAb) targeting immune cells or tumors. In this matter, thera-
peutic Ab (summarized in Table 1) that can be used either alone 
or in combination with RT, CT, or IT are involved in depletion 
of Tregs (anti-CD25) (99) or target (i) co-stimulatory molecules 
such as CD40 (100, 101), OX40 (CD134) (102), and 4-1BB 
(CD137) (103, 104) on immune cells; (ii) checkpoint inhibitors 
PD-1, PD-L1 (103, 105) and CTLA-4 (99, 104); and (iii) cell 
growth factors or their receptors, e.g., epidermal growth factor 
receptor (EGFR), vascular endothelial growth factor (VEGF), 
and VEGFR (106, 107), all of which will be discussed in the 
following paragraph.
Co-stimulatory Molecules as Target to 
improve RT and CT-induced Systemic 
immune Responses
CD40
CD40, a member of the TNF receptor (TNF-R) family, is expressed 
on APCs such as DCs, B cells, and macrophages. Interaction with 
its ligand (CD40L) on activated T cells promotes their activation 
and subsequently the induction of adaptive immune responses. 
Furthermore, the interaction between CD40 and its natural ligand 
(CD40L, CD154) was shown to modulate the growth of malignant 
B cells, thus CD40-related therapies have been considered for a 
range of cancer entities, including B-cell malignancies, leukemia, 
and multiple myelomas (MMs) (108), making it an attractive 
target structure. CD40 agonists mediate tumor cell death and in 
combination with DC activation anti-tumor immune responses. 
Pre-clinical models showed that anti-CD40 therapy in combina-
tion with RT results in a CD8 T-cell-dependent immunity to 
B-cell lymphoma (101). Currently, there are several anti-CD40 
antibodies such as CP-870,893, dacetuzumab, and lucatumumab 
either as stand-alone treatments or in various combinations 
under investigation, such as a phase 1A/II study (NTC00670592) 
of patients with advanced non-Hodgkin lymphoma (NHL) or 
Hodgkin lymphoma (HL), which demonstrated a modest lucatu-
mumab activity (109). However, there is still a lack of clinical data 
assessing the efficacy of targeting CD40 especially in combinatory 
therapy regimens with RT, CT, and other ITs, which is why further 
investigations are necessary.
OX40
OX40 (CD134), a co-stimulatory molecule expressed on acti-
vated T cells, is also part of the TNF-R superfamily. A phase I 
trial (NCT01644968), focusing on anti-OX40 monotherapy with 
a murine agonistic anti-human Ox40 mAb (9B12) in patients 
with metastatic solid malignancies showed an increased prolif-
eration of CD4+/FoxP3- and CD8+ T cells as well as CD3-/NK 
cells. While anti-OX40 treatment was well tolerated with mild to 
mediate side effects, 12 out of 30 patients showed regression of at 
least one metastatic lesion (110). In order to increase this effect, a 
variety of combinatory therapy strategies of anti-OX40 treatment 
with CT, RT, or other IT are currently under investigation. For 
instance, a murine model of stereotactic body radiation therapy 
(SBRT) of lung cancer showed significant enhancement of tumor-
free survival through intensified tumor antigen-specific CD8+ 
T-cell responses under RT combined with adjuvant anti-OX40 
therapy (111). Furthermore, a phase I/II trial with SBRT plus 
anti-OX40 in patients suffering from metastatic breast cancer 
(NCT01862900) and a phase Ib trial with cyclophosphamide, RT, 
and anti-OX40 in patients with progressive metastatic prostate 
cancer (NCT01303705) are currently ongoing with results not yet 
published.
CD137 (4-1BB)
CD137, expressed on activated CD4+ and CD8+ T cells, as well 
as on several APCs, including DCs, activated B cells, and mac-
rophages, co-stimulates T-cell activation and clonal expansion 
after T-cell receptor (TCR) engagement through interactions 
with CD137-ligand. Importantly, the therapeutic use of 4-1BB 
agonists in vivo leads to a biased CD8+ T-cell activation with a 
concomitant decline of B cells, NK, and CD4+ T cells in an IFN-, 
TNF-, TGF-β, and IDO-dependent fashion (112). Furthermore, 
stimulation of CD137 on tumor endothelial cells via an agonistic 
antibody upregulates ICAM1, VCAM1, and E-selectin and 
thereby enhances T-cell recruitment into tumor tissue (113). 
In murine lung (M109) and breast carcinoma (EMT6) models, 
the efficiency of BMS-469492, another agonistic CD137 mAb, 
in combination with RT was evaluated. In the case of lung 
carcinoma treatment only a combination of the antibody with 
RT administered as a high radiation dose of 15 Gy resulted in 
an enhanced tumor response. In the breast cancer model, the 
CD137 agonist alone already led to significant tumor growth 
inhibition that could even be potentiated by using high single 
doses or fractionated radiation. The authors concluded that 
the different responses in the two models could result from 
differences in intrinsic immunogenicity of the different tumor 
entities and that anti-CD137 antibodies may not only be used 
as a stand-alone therapy but in combination with conventional 
anti-cancer treatments, e.g., RT (114). Furthermore, the combi-
nation of RT and anti-CD137 in an intracranial glioma model 
resulted in complete tumor elimination and prolonged survival 
in 67% of the mice. The combination therapy highly increased 
the numbers of tumor-infiltrating CD4+ and CD8+ lymphocytes 
as well as IFN-γ production (115). Thus, based on promising 
pre-clinical data of combining anti-CD137 and RT/CT, two cur-
rently ongoing clinical phase I studies have been initiated. While 
NCT00461110 investigates agonistic anti-CD137 (BMS-663513) 
treatment in combination with chemo-radiation (RT, paclitaxel, 
carboplatin) in non-small cell lung carcinoma (NSCLC) patients, 
NTC00351325 focuses on a combination therapy of BMS-663513 
with CT (paclitaxel, carboplatin) in patients suffering from recur-
rent ovarian carcinoma.
TABLe 1 | Selected monoclonal antibodies and tyrosine kinase inhibitors against co-stimulatory and checkpoint molecules and growth factors that are 
in clinical phase i–iii trials either alone or in combination with RT, CT or immunotherapy.
Target Drug Developer Target disease (not all listed)
Co-stimulatory molecules
CD40 CP-870,893
Dacetuzumab
Lucatumumab
Pfizer
Seattle Genetics, Inc.
Novartis
Melanoma; pancreatic carcinoma; renal-cell carcinoma; breast cancer
Diffuse large B-cell lymphoma (DLBCL); chronic lymphocytic leukemia (CLL);  
non-hodgkin’s lymphoma (NHL); multiple myeloma (MM)
CLL; NHL; MM
CD134 (OX40) MEDI6469 AstraZeneca Advanced solid tumors; aggressive B-cell lymphomas; HNC; metastatic prostate cancer
CD137 BM-663513 Bristol-Myers Squibb (BMS) Melanoma; advanced solid malignancies; B-cell malignancies
Checkpoint inhibitors
CTLA-4 Tremelimumab
Ipilimumab
Pfizer
BMS
Metastatic melanoma; HNSCC; NSCLC; advanced solid malignancies
Yervoy™ approved for unresectable or metastatic melanomaa; lymphoma; NSCLC; 
HNC; prostate, pancreatic, liver, lung, kidney and renal-cell cancer; melanoma
PD-1 Nivolumab
Pembrolizumab
Pidilizumab
BMS
Merck
CureTech Ltd
Obvido® approved for unresectable or metastatic melanoma and NSCLCa; MM; NHL 
Renal-cell carcinoma (RCC); advanced solid tumors; melanoma; NSCLC
Keytruda® approved for advanced or unresectable melanomaa; NSCLC; HNSCC; 
lymphoma; breast cancer; malignant glioma; melanoma
MM; gliomas; lymphomas
PD-L1 BMS-936559
MEDI4736
BMS
AstraZeneca
Recurrent solid tumors
Advanced solid tumors; NSCLC; HNSCC; GBM
Growth factor inhibitors
EGFR Cetuximab
Panitumumab
Gefitinib
Erlotinib
BMS
Amgen
AstraZeneca
Genentech/Roche
Erbitux® approved for K-ras wild-type, EGFR-expressing metastatic colorectal cancer 
and recurrent/metastatic HNSCCa; NSCLC; HNSCC; colorectal cancer
Vectibix™ approved for colorectal cancera; HNSCC; colorectal cancer
Iressa® approved for NSCLCa; HNC; skin, breast, colorectal cancer; GBM; NSCLC
Tarceva® approved for NSCLC and pancreatic cancera; HNC; prostate, breast, 
esophageal, colorectal cancer; NSCLC; pancreatic cancer
HER2/neu  
receptor
Trastuzumab Genentech/Roche Herceptin® approved for HER2-overexpressing breast cancer and HER2-overexpressing 
metastatic gastric or gastroesophageal (GE) junction adenocarcinomaa; breast cancer; 
NSCLC
VEGFRs, PDGFRs, 
FLT-3, c-Kit, RET; 
CSF-1R
Sunitinib Pfizer Sutent® approved for pancreatic neuroendocrine tumors (pNET); kidney cancer and 
gastrointestinal stromal tumor (GIST)a; pNET; kidney cancer; GIST; RCC, pancreatic and 
bladder cancer
VEGFRs, PDGFRs, 
RAF, FLT-3, c-Kit, 
RET
Sorafenib Bayer Nexavar® approved for recurrent or metastatic, progressive differentiated thyroid 
carcinoma (DTC), unresectable hepatocellular carcinoma (HCC) and advanced RCCa; 
HCC; RCC, bladder cancer; brain neoplasms; advanced solid tumors
VEGFRs Axitinib Pfizer Inlyta® approved for advanced RCCa; advanced gastric cancer; hepatocellular and 
colorectal carcinoma; prostate cancer; GBM; RCC; NSCLC
VEGFRs, PDGFRs, 
c-Kit
Pazopanib GlaxoSmithKline Votrient® approved for advanced soft tissue sarcoma and RCCa; ovarian cancer; 
fallopian tube cancer; peritoneal carcinoma; NSCLC; RCC
VEGF-A Bevacizumab Genentech/Roche Avastin® approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal 
cancer, recurrent/metastatic cervical cancer, metastatic HER2 negative breast cancer, 
RCC, GBM, NSCLCa; advanced cancers
aFDA-approved drugs.
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Checkpoint inhibitors as Targets to 
improve RT-induced Systemic 
immune Responses
In order to ensure peripheral tolerance and to avoid overshoot-
ing immune reactions, endogenous mechanisms to dampen 
T cells have been evolved. Cytotoxic T lymphocyte-antigen-4 
(CTLA-4) and PD-1 are major negative co-stimulatory molecules 
expressed on activated T cells (116–118). While CTLA-4 regu-
lates early stages of T-cell activation, PD-1 limits the activity of 
T cells in peripheral tissues during inflammatory response and 
is therefore a major immune resistance mechanism in the tumor 
microenvironment.
CTLA-4
T-cell activation and survival are dependent on positive signal-
ing from the TCR as well as co-stimulatory molecules such as 
CD28. CTLA-4 is an inhibitory molecule that is upregulated 
on the surface of effector T cells and competes with CD28 for 
the binding to CD80/86 (B7.1 and B7.2). Under physiological 
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conditions, this limits the T-cell response and helps to maintain 
T-cell homeostasis (119). However, with regard to cancer treat-
ment, the down-regulation of a tumor-specific T-cell response 
is an unwanted scenario, thus favoring an antagonistic CTLA-4 
therapy. Indeed, various pre-clinical and clinical studies have 
already proven the efficiency of anti-CTLA-4 therapy, especially 
for melanoma in multimodal settings. This tumor entity has a 
high prevalence for somatic mutations (120) and is therefore 
suitable for being specifically targeted by activated immune cells.
Pre-clinical melanoma models showed that tumors do not 
always respond to an anti-CTLA-4 mAb alone, while additive 
treatments with GM-CSF (121) or activation of the T-cell co-
stimulatory receptor 4-1BB (122) are able to promote an anti-
tumor response. Furthermore, a combination of RT and CTLA-4 
mAb treatment prolonged the OS in an orthotopic GL261 glioma 
model, whereas CTLA-4 mAb alone was not able to extend the 
survival in comparison to untreated controls. A triple combination 
of RT, anti-CTLA-4, and anti-CD137 further improved survival in 
this pre-clinical model through a CD4+ T-cell-dependent manner 
and created a glioma-specific protective memory response (104). 
Dewan and colleagues reported an abscopal effect in breast (TSA) 
and colon cancer (MCA38) models: An increased frequency of 
CD4+ and CD8+ tumor-infiltrating lymphocytes along with 
tumor-specific IFN-γ production was observed after a combined 
administration of anti-CTLA-4 mAb (9H10) and fractionated 
(3 ×  8  Gy or 5 ×  6  Gy fractions in consecutive days), but not 
single-dose RT with 20 Gy. Furthermore, three doses of 8 Gy in 
combination with anti-CTLA-4 was able to induce a more potent 
systemic effect and higher frequency of tumor-specific T cells 
than five doses of 6 Gy plus anti-CTLA-4 (36), suggesting that 
fractionation influences the induction of anti-tumor immune 
responses with further immune stimulation (76).
Two fully humanized anti-CTLA-4 antibodies, tremelimumab 
and ipilimumab, advanced for testing in clinical trials. Most 
studies so far are focused on melanoma, where treatment-related 
adverse effects were found to be manageable (123–125). Various 
phase I and II studies evaluated anti-CTLA-4 therapy in a stand-
alone therapy setting or in various combinations such as tumor 
antigen-loaded DCs (126, 127), the TLR9 agonist PF-3512676 
(128), IFN-α-2b (129) or in combination with various chemo-
therapeutics (for further reading, refer to NCT00257205 (130), 
NCT02262741, NCT02319044, NCT02369874, NCT02352948, 
NCT02040064).
In summary, current study results show the importance of 
investigating the optimal dose, schedule, and combination of 
anti-CTLA-4 antibodies with other therapy options to ensure 
high patient safety and efficacy in selected cancer entities.
As approximately 50% of cancer patients receive RT with the 
primary goal of local tumor control (4), combinatory therapies 
of RT with immune checkpoint inhibitors targeting T cells might 
be a good synergistic option to induce additional systemic anti-
tumor immune responses, as it has already been shown in many 
mouse models (Table 2) (36, 131–134). A tremelimumab/SBRT 
pilot study for patients suffering from unresectable pancreatic 
cancer (NCT02311361) is currently recruiting patients.
Another anti-CTLA-4 mAb is ipilimumab, as with tremeli-
mumab, patients with advanced metastatic cancer can benefit 
from it. Adverse side effects such as strong autoimmune reactions 
have been observed in a dose-dependent manner in various phase 
I/II trials (163–165). An increase of the ipilimumab-induced 
response rate might be achieved through a combination with 
immunogenic RT. Postow et  al. described the first case of a 
systemic immune-mediated effect in a patient suffering from 
metastatic melanoma that has been treated with ipilimumab 
and a concomitant palliative RT (28.5 Gy in three fractions) that 
correlated with beneficial immune changes in the peripheral 
blood when RT was added (136). Five months after RT and 
an additional administered ipilimumab dose, RT-treated and 
non-RT-treated lesions had regressed and remained stable with 
minimal disease progression after 10  months, as confirmed by 
computed tomography scans. A second case of complete systemic 
response after a combined treatment of ipilimumab followed by 
high-dose stereotactic RT of 54 Gy in three fractions to two out 
of seven metastatic liver lesions was reported in a patient with 
advanced melanoma (137). Several studies have also provided 
evidence of ipilimumab effectiveness in cases of melanoma with 
brain metastases (165, 166). Hence, in a retrospective study of 21 
patients suffering from advanced melanoma and brain metasta-
ses, Grimaldi and colleagues (138) reported abscopal responses 
in 52% of patients receiving an initial ipilimumab therapy fol-
lowed by localized RT. Furthermore, this systemic response was 
correlated with prolonged OS.
These promising results of combined ipilimumab and RT 
treatment spiked the interest and led to the initiation of studies for 
other cancer entities than melanoma. Likewise, a phase I/II study 
in patients with metastatic castration-resistant prostate cancer 
(mCRPC) suggests the induction of clinical anti-tumor activity 
with disease control and manageable adverse effects after 10 mg/
kg of ipilimumab and RT with 8  Gy per lesion (167). A phase 
III trial (NCT00861614) evaluating ipilimumab administration 
(10 mg/kg) vs. placebo after RT in patients suffering from mCRPC 
with disease progress after docetaxel reported an improvement 
of median OS within the ipilimumab group (11.2 vs. 10 months 
in the placebo group). Conversely, most of the common adverse 
effects (26 vs. 3%) and four deaths occurred in patients receiving 
ipilimumab treatment vs. placebo (139). Just recently, a systemic 
response was reported in a patient suffering from metastatic 
NSCLC 2.5 months after the start of a combined ipilimumab and 
fractioned RT (140). This suggests that a combination of local 
RT alongside IT could be a useful approach to further improve 
clinical outcome of patients with metastatic disease (2). Therefore, 
various phase I/II studies of combined RT and ipilimumab 
administration for metastatic NSCLC (NCT02221739), advanced 
cervical cancer (NCT01711515), metastatic cancers of liver and 
lungs (NCT02239900), and patients with melanoma and brain 
metastases (NCT02115139) have been initiated and are currently 
recruiting patients.
PD-1/PD-L1 (B7-H1)
PD-1, another negative regulator of TCR signaling, and its ligand 
PD-L1 play an important role in modulating T-cell activity not 
only in physiological conditions but also in the tumor micro-
environment of various cancer entities. Thus, blockage of PD-1 
and PD-L1 interaction through mAb is a promising strategy to 
TABLe 2 | Systemic effects observed in pre-clinical and clinical studies after multimodal treatment of RT, CT, and immunotherapy.
Checkpoint Tumor type Treatment Systemic effects + key mediator Reference
PReCLiNiCAL MOUSe-MODeLS
CTLA-4 Metastatic mammary carcinoma 
(4T1)
RT (2 × 12 Gy) of primary tumor + anti-CTLA-4 mAb i.p. (3×) Inhibition of lung metastases, ↑CD8+ CTLs (131)
Metastatic mammary carcinoma 
(4T1)
RT (2 × 12 Gy) of primary tumor + anti-CTLA-4 (9H10) mAb 
i.p. (3×)
Inhibition of lung metastases, increased survival, ↑CD8+ CTLs (132)
Mammary carcinoma (TSA), colon 
carcinoma (MCA38)
RT of primary tumor (20 Gy, 3 × 8 Gy, 5 × 6 Gy) + anti-CTLA-4 
(9H10) mAb i.p. (3×)
Growth-inhibition of irradiated and non-irradiated tumor, ↑CD8+ CTLs and 
CD4+ Th-cells, iFNγ
(36)
PD-1 Melanoma (B16), renal cortical 
adenocarcinoma (RENCA)
SABR (15 Gy) + anti-PD-1 mAb (5×) Near-complete regression of primary tumor, 66% size reduction of  
non-irradiated tumor,↑CD8+ CTLs
(133)
Glioma (GL261) RT (10 Gy) + anti-PD-1 mAb i.p. Tumor regression and long-term survival,↓ Tregs, ↑ CD8+ CTLs, iFNγ (105)
Melanoma (B16), breast carcinoma 
(4T1-HA)
RT (12 Gy) + anti-PD-1 mAb i.p. (3×) Tumor regression and tumor control, ↓ Tregs, ↑ CD8+ CTLs (135)
PD-L1 Mammary carcinoma (TUBO) SABR (12 Gy) + anti-PD-L1 mAb (4×) Size reduction of primary and abscopal tumors, ↓ MDSC, ↑ CD8+ T-cells (134)
CD137 (4-1BB) Lung carcinoma (M109) RT (5, 10 or 15Gy) + anti-CD137 (BMS-469492) mAb i.v. (3×) Tumor growth retardation at a dose of 15 Gy (114)
Breast carcinoma (EMT6) RT (5, 10, 15Gy, 11 × 4 Gy) + anti-CD137 (BMS-469492) mAb 
i.v. (3×)
Enhanced tumor growth retardation at all radiation doses (114)
Glioma (GL261) RT (2 × 4 Gy) + anti-CD137 mAb i.p. (3×) Tumor eradication, prolonged survival (6/9), rejection of challenging tumors 
(5/6), ↑CD8+ CTLs and CD4+ Th-cells, iFNγ
(115)
CTLA-4 + CD137 Glioma (GL261) RT (10 Gy) + anti-CD137 and anti-CTLA-4 mAb i.p. (3×) Prolonged survival, ↑CD8+ CTLs and CD4+ Th-cells (104)
CLiNiCAL STUDieS
Checkpoint inhibitors
CTLA-4 Metastatic melanoma (n = 1) RT (28.5 Gy in 3 fractions) + ipilimumab Regression of irradiated and non-irradiated tumor lesions, stable lesions 
and minimal disease 10 months after RT
(136)
Metastatic melanoma (n = 1) RT (54 Gy in 3 fractions) + 4 cycles of ipilimumab Regression of irradiated and non-irradiated tumor lesions, CR, no 
evidence of disease 12 months after RT
(137)
Melanoma with brain metastasis 
(n = 21)
Four cycles of ipilimumab + loco-regional RT 13/21 LR, 11/21 with LR abscopal effect and 2/21 stable disease (138)
mCRPC (n = 799) [NCT00861614] RT (1 × 8 Gy) per lesion + 1–4 doses of ipilimumab (n = 399) or 
placebo (n = 400)
Improved median OS (139)
Metastatic NSCLC (n = 1) RT (5 × 6 Gy) + four cycles of ipilimumab Regression of irradiated and non-irradiated tumor lesions (140)
PD-1 Melanoma, NSCLC, mCRPC, 
colorectal cancer, and renal cancer 
(n = 236)
nivolumab Cumulative response rates in 14/76 among NSCLC patients, in 26/94 of 
melanoma patients and in 9/33 renal-cell cancer patients
(141)
Advanced melanoma Pembrolizumab (lambrolizumab; MK-3475) 52% response rate drug-related adverse effects were reported by 79% of 
patients, with 13% reporting grades 3 and 4 secondary effects
(142)
Patients with DLBCL undergoing 
AHSCT [NCT00532259]
AHSCT + 3 doses pidilizumab At 16 months, PFS was 0.72, among the 35 patients with measurable 
disease after AHSCT, overall response rate was 51%, ↑ circulating 
lymphocyte subsets including PD-L1-bearing lymphocytes
(143)
PD-L1 Dose-escalation study in patients 
with NSCLC, melanoma, colorectal, 
renal-cell, ovarian, pancreatic, 
gastric, and breast cancer (n = 207) 
[NCT00729664]
Administration of BMS-936559 in 6-week cycles; up to 16 
cycles
Objective response rate in 9/52 in melanoma, in 2/17 in renal-cell cancer,  
in 5/49 in NSCLC, and in 1/17 in ovarian cancer
(144)
(Continued)
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Checkpoint Tumor type Treatment Systemic effects + key mediator Reference
Growth factor inhibitors
VEGF-A Advanced nasopharyngeal 
carcinoma (n = 44) [NCT00408694]
IMRT (50–70 Gy) + CT + concurrent and adjuvant BEV Localregional PFS (83.7%) and distant metastasis-free interval (90.8%), 
PFS (74.7%), OS (90.9%) within 2 years median followup
(145)
Advanced colorectal carcinoma 
(n = 19)
RT (15x–3.4 Gy) + concurrent and adjuvant BEV + CT CR (68.5%) and PR (21.1%) within 2 years median follow (146)
Newly diagnosed GBM 
[NCT00943826]
RT (60 Gy) + concurrent and adjuvant TMZ + BEV (n = 458) or 
placebo (n = 463)
Improved PFS (147)
Newly diagnosed GBM (n = 621) 
[NCT00884741]
RT (60Gy) + concurrent and adjuvant TMZ + BEV or placebo Improved PFS (148)
EGFR LA-HNC [NCT00004227] RT with concurrent cetuximab (n = 211) or RT alone (n = 213) Improved median OS (149)
Unresectable LA-SCCHN (n = 60) 
[NCT00096174]
RCT with concurrent and adjuvant cetuximab Improved median OS in HPV(+) tumors (150)
Esophageal cancer 
[ISRCTN47718479]
RCT with cetuximab (n = 129) or RCT alone (n = 129) ↓ Survival in cetuximab group (151)
Unresectable NSCLC  
[SWOG 0023]
RCT with adjuvant gefintinib (n = 118) or placebo (n = 125) ↓ Survival in gefinitib group (152)
LA-HNC (n = 66) CRT + concurrent and adjuvant gefintinib CR (90%), PFS (72%), OS (74%) within 3.5 years median followup (153)
Metastatic NSCLC (n = 24) SBRT + CT with neoadjuvant, concurrent and adjuvant erlotinib Improved PFS and OS (154)
Advanced cervical cancer (n = 36) RCT with neoadjuvant, concurrent erlotinib Improved PFS and OS (155)
Lung adenocarcinoma with brain 
metastases
WBRT with concurrent and adjuvant erlotinib  
(n = 23) or WBRT alone (n = 21)
Median local PFS 6.8 vs. 10.6 month (mOS: 6.8 vs. 10.6 month, response 
rate 54.84 vs. 95.65%) in RT vs. RT + E
(156)
Newly diagnosed GBM (n = 65) RCT with concurrent and adjuvant erlotinib Median PFS 8.2 vs. 4.9 month (mS: 19.3 vs. 14.1 month) RCT + E vs. 
historical controls (only RCT)
(157)
EGFR + VEGF-A LA-HNC (n = 27) [NCT00140556] Neoadjuvant BEV and/or erlotinib concurrent CRT + BEV and 
erlotinib
CR (96%), local control (85%) and distant metastasis-free survival rate 
(93%), PFS (82%), OS (86%) within 3 years median followup
(158)
VEGFR, PDGFR, 
KIT, RAF
Advanced hepatocellular  
carcinoma (n = 40)
RT with concurrent and adjuvant Sorafenib (S) No improved efficacy of RT + S compared to RT alone (159)
Newly diagnosed GBM (n = 47) RCT with adjuvant sorafenib (S) No improved efficacy of RCT + S compared to RCT alone (160)
RTK inhibitor Patients with oligometastases 
(n = 25) [NCT00463060]
Sunitinib  + IGRT (10 × 5 Gy) Local (75%) and distant (52%) tumor control, PFS (56%), OS (71%) within 
18-month median followup
(161)
Patients with oligometastases 
(n = 46)
Sunitinib + SBRT (10 × 5 Gy) Local (75%) and distant (40%) tumor control, PFS (34%), OS (29%) within 
4-year median followup
(162)
Co-stimulatory molecules
CD40 Advanced NHL (n = 74)or HL 
(n = 37) [NTC00670592]
Escalating doses of lucatumumab (once weekly for 4 weeks of 
an 8-week cycle)
Modest activity in relapsed/refractory patients with advanced lymphoma (109)
↑, increase; ↓, decrease; NSCLC, non-small cell lung carcinoma; mCRPC, metastatic castration-resistant prostate cancer; GBM, glioblastoma multiforme; LA-HNC, locally advanced head and neck cancer; LA-SCCHN, locally 
advanced squamous cell head and neck cancer; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; SBRT, stereotactic body radiation therapy; SABR, stereotactic ablative RT; IMRT, 
intensity modulated radiation therapy; IGRT, image-guided radiotherapy; WBRT, whole brain radiotherapy; AHSCT, autologous hematopoietic stem-cell transplantation; OS, overall survival; PFS, progression-free survival; CR, complete 
response; PR, partial response; LR, local response; BEV, bevacizumab; R-ICE, rituximab, ifosfamide, carboplatin and etopside; MDSCs, myeloid-derived suppressor cells.
TABLe 2 | Continued
O
ctober 2015 | Volum
e 6 | A
rticle 505
10
D
erer et al.
R
adio-im
m
unotherapy-induced im
m
unogenic cancer cells
Frontiers in Im
m
unology | w
w
w
.frontiersin.org
October 2015 | Volume 6 | Article 50511
Derer et al. Radio-immunotherapy-induced immunogenic cancer cells
Frontiers in Immunology | www.frontiersin.org
overcome tumor-escape from a tumor-specific immune response 
(168, 169).
Pre-clinical studies have demonstrated an enhancement of 
anti-tumor immunity through a combination of RT together 
with antibody-mediated PD-1 blockade (133–135). For instance, 
the effectiveness of treatment of mouse melanoma and renal-
cell tumors with stereotactic ablative radiotherapy (SABR) was 
dependent on PD-1 expression. Only 20% of PD-1 KO mice 
and none of the wild-type mice survived beyond 40  days. The 
combination of SABR with PD-1 blockade resulted not only in 
an almost complete regression of the irradiated primary tumor, 
but also in a 66% size reduction of the non-irradiated secondary 
tumors. Park et  al. therefore suggest a SABR-induced systemic 
tumor-specific immune response also targeting the secondary 
non-irradiated tumors that can further be increased by PD-1 
blockade (133). Of note is that optimal timing of RT in combina-
tion with a checkpoint blockade is mandatory: since IR tempo-
rarily increases the expression of PD-1L on tumor cells (134), a 
concurrent application is suggested. Addition of anti-PD-L1 mAb 
after RT does not result in prolonged survival of tumor-bearing 
mice (170, 171).
Single-agent trials have already been initiated using the anti-
PD-1 mAbs nivolumab, pembrolizumab, and pidilizumab, as 
recently summarized by Philips and Atkins (172). Those studies 
include planned or ongoing phase I–II trials of anti-PD-1 mAb 
monotherapy for various cancer entities, such as lymphoma 
(NCT02038946, NCT02038933, NCT01953692), NSCLC 
(NCT02066636, NCT01840579), hepatocellular carcinoma 
(HCC) (NCT01658878), HNSCC (NCT02105636), melanoma 
(NCT02374242, NCT01844505, NCT02306850), and glioma 
(NCT02337686, NCT02359565, NCT01952769), respectively, 
either alone or in comparison to CT or IT. A phase I trial inves-
tigating safety and reactivity of nivolumab in 236 patients with 
melanoma, NSCLC, mCRPC, colorectal cancer, and renal cancer 
concluded cumulative response rates in 14 of 76 among NSCLC 
patients, in 26 of 94 of patients suffering from melanoma and in 
9 of 33 renal-cell cancer patients. Anti-PD-1 treatment-related 
toxic effects (grades 3 and 4) occurred in 14% of the patients 
(141). A phase I trial with BMS-936559, a PD-L1-specific Ab in 
NSCLC, melanoma, colorectal, renal-cell, ovarian, pancreatic, 
gastric, and breast cancer (NCT00729664) patients resulted in an 
objective response rate in 9 of 52 in melanoma, in 2 of 17 in renal-
cell cancer, in 5 of 49 in NSCLC, and in 1 of 17 in ovarian cancer, 
while drug-related adverse effects of grades 3 and 4 occurred in 
9% of treated patients (144). A clinical investigation of lambroli-
zumab (MK-3475) in patients with advanced melanoma showed 
a 52% response rate. However, during the treatment drug-related 
adverse effects were reported by 79% of patients, with 13% report-
ing grades 3 and 4 secondary effects (142). These investigations 
lead to a FDA approval of pembrolizumab (formerly MK-3475 
and lambrolizumab) in patients suffering from advanced or non-
resectable melanoma that are no longer responsive to standard 
medications.
As it has been shown by Ansell et al., cells within the microen-
vironment in lymphomas express PD-L1, and with intratumor-
ally found T cells also expressing PD-1, this discovery provides 
the possibility to successfully target this immune checkpoint 
also in malignancies of hematopoietic origin (173). In the case 
of pidilizumab, an international phase II study was conducted 
in patients with diffuse large B-cell lymphoma (DLBCL) that are 
undergoing autologous hematopoietic stem-cell transplantation 
(AHSCT). The investigators discovered that among 35 out of 
66 patients with measurable disease after AHSCT, the overall 
response rate after pidilizumab was 51%. In addition to that, an 
increase of activated CD4+ helper and central memory T cells 
along with circulating CD8+ peripheral and central memory T 
cells was found, which was the first reported clinical activity of 
PD-1 blockage in DLBCL (143). Recently, a study examining 
nivolumab in relapsed or refractory Hodgkin’s lymphoma revealed 
a substantial therapeutic activity with an objective response rate 
of 87% and an acceptable safety profile in the evaluated cases 
(NCT01592370) (174).
In summary, PD-1 or PD-1L antagonistic mAb are able to 
promote a positive anti-tumor immune response in patients, 
while the response rate depends on the tumor entity. Thus, a 
combination therapy of anti-PD-1 mAb with RT could further 
improve the outcome and especially be an efficient strategy in 
the management of metastatic disease. The interactions of mul-
tiple co-stimulatory and inhibitory molecules regulating T-cell 
responses that can be targeted to strongly enhance radio(chemo)
therapy (RCT)-induced anti-tumor immune responses are sum-
marized in Figure 2.
Growth Factors as Targets for Cancer 
Therapeutics
The activation of receptors by growth factors such as EGF, VEGF, 
transforming growth factor-α (TGF-α), and basic fibroblast 
growth factor (bFGF) triggers various cellular processes, includ-
ing proliferation, differentiation, apoptosis, migration, adhesion, 
invasion, vascular permeability, or angiogenesis. As EGF and 
VEGF signaling pathways are a key feature in the development, 
progression, and metastatic formation in a wide range of cancer 
entities, they function as important targets for therapeutic Ab 
(175). In addition, pre-clinical models demonstrated a broad 
efficacy for anti-EGFR and anti-VEGF Abs alone (176–178) 
and in combination with RT (179). As in the case of checkpoint 
inhibitors, concurrent application should be most effective, 
since, e.g., VEGF-C expression is enhanced after irradiation 
(180). While many inhibitors are currently undergoing clinical 
evaluation, several others are already used in cancer therapy 
(Figure 2). Some of the FDA-approved inhibitors are anti-EGFR 
mAb that either work via binding the extracellular domain of 
EGFR (cetuximab, panitumumab, and trastuzumab) or target the 
intracellular EGFR domain such as the tyrosine kinase inhibi-
tors gefitinib and erlotinib (181). FDA-approved anti-VEGFR 
mAb, on the other hand, inhibit angiogenesis through VEGF-A 
blocking [e.g., bevacizumab (BEV)] or also act as VEGFR tyros-
ine kinase inhibitors such as sunitinib, sorafenib, axitinib, and 
pazopanib (182, 183). They are approved for a variety of tumor 
entities, including metastatic colorectal cancer, gastric or gastro-
esophageal carcinoma, renal-cell carcinoma (RCC), advanced 
soft tissue sarcoma, pancreatic neuroendocrine tumors (pNET), 
breast cancer, NSCLC, HNSCC, and glioblastoma. Several 
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FiGURe 2 | interactions of various co-stimulatory and inhibitory molecules regulate T-cell responses, tumor cell behavior, and vascularization. 
Immunotherapies with agonistic or antagonistic monoclonal antibodies have been developed to modulate these interactions by stimulating or blocking their activity. 
In the figure, a selection of important molecular interactions, their most relevant cellular source (not exclusive), and examples of antagonistic (red lines) or agonistic 
(green arrow) monoclonal antibodies as well as inhibitors are displayed. Activating receptors are depicted in green, suppressive receptors are shown in red, ligands 
are gray. For further information, please refer to the main text.
reports about the safety and efficacy of growth factor inhibitors 
either in the form of monotherapy or as a combinatory therapy 
paired with IT, CT, or RT have been released. However, targeting 
VEGF or EGFR alone does not always provide adequate tumor 
control in the clinic. In the next section, we will therefore focus 
on FDA-approved inhibitors in combinatory therapy settings 
together with RT or RCT.
Growth Factor inhibitors and RT
Patients suffering from loco-regional advanced squamous-cell 
carcinoma of the head and neck cancer (HNC) being treated in 
a phase III trial with a high-dose RT in combination with weekly 
cetuximab administration showed an increased loco-regional 
tumor control (24.4 vs. 14.9  months), along with increased 
median OS (49.0 vs. 29.3 months), increased median progression-
free survival (PFS,17.1 vs. 12.4 months), and reduced mortality in 
comparison to high-dose RT monotherapy (149). A combination 
of erlotinib with R(C)T is also able to enhance OS as well as PFS in 
patients with metastatic NSCLC (154), cervical cancer (155), lung 
adonocarcinoma (184), or GBM (157). Tong et al. demonstrated 
a protective effect of a combination of sunitinib with RT on oligo-
metastases (161). Their results were confirmed by Kao et al. who 
found a 75% local control and 40% distant control of oligome-
tastases, a PFS of 34%, and an OS of 29% over a 4-year period in 
patients with HNC, liver, lung, kidneys, and prostate cancers that 
have been treated with SBRT and concomitant sunitinib therapy 
(162). However, a combination therapy of RT and sorafenib in 
comparison with standard therapy was not able to enhance the 
efficacy in GBM and hepatocellular carcinoma (159, 160, 185).
Growth Factor inhibitors and R(C)T
A phase II study demonstrated a near-complete or complete 
tumor response in 53% of patients treated with a combination of 
panitumumab and RCT vs. 32% of patients treated with standard 
RCT in patients with advanced rectal cancer with wild-type 
KRAS (186). In vitro studies on this matter also demonstrated an 
elevated level of radiosensitivity (187), while the clinical relevance 
of a combination of RT and adjunctive trastuzumab therapy is still 
under investigation. A phase II study investigating the effects of 
gefitinib with concomitant RCT in locally advanced HNC found 
a 4-year enhanced OS (74%), PFS (72%) and disease-specific 
survival rates (89%), respectively (153). BEV is the first approved 
angiogenesis inhibitor and is used in metastatic colorectal cancer, 
NSCLC, and breast cancer. As a result of the poor prognosis of 
patients with GBM and thus a need for new therapy modalities, 
the combination of standard RCT and anti-angiogenic antibodies 
such as BEV might be a promising approach in the treatment of 
this tumor entity. Therefore, various clinical trials dealt with this 
notion and revealed an extended PFS and improved life quality 
in newly diagnosed GBM patients that have been treated with 
standard RCT and BEV, whereas no change in OS was observed 
(147, 148, 188). BEV has also been examined in various other 
entities: an addition of BEV to RCT in pancreatic adenocarci-
noma resulted in survival rates similar to those of standard 
approaches (189), in cases of nasopharyngeal carcinoma it was 
able to promote OS and has been linked to a delayed progression 
of distant metastases (145). Furthermore, an application of BEV 
in metastatic colorectal cancer resulted in high rates of long-term 
complete responses (CRs) (146). A simultaneous VEGF-A and 
October 2015 | Volume 6 | Article 50513
Derer et al. Radio-immunotherapy-induced immunogenic cancer cells
Frontiers in Immunology | www.frontiersin.org
EGFR blockade (BEV  +  erlotinib) in locally advanced head 
and neck cancer (LA-HNC) together with concurrent RCT are 
favorable when being compared to historical controls (158).
Taken together, all these data suggest a synergized effect of 
combination treatment of R(C)T with VEGF and/or EGFR 
inhibitors as seen in NSCLC cells reported by Kriegs et al. (190). 
Most of the approved mAb used in cancer IT are generally well 
tolerated in humans (191). Conversely, mAb application can also 
be associated with an increased risk of unwanted and possibly 
even fatal adverse effects (191–194), including cytokine release 
syndrome, induced autoimmunity, organ toxicity, opportunistic 
infections, and even cancer as a result of immune suppression. 
This shows how, despite the success of therapeutic Ab, their clini-
cal efficacy greatly depends on tumor type, treatment duration, 
administered dose, and combination-therapy options. With this 
in mind, a new and promising approach in IT, the adoptive cell 
transfer, might be another useful therapy option to be combined 
with RT. Here, autologous T cells that are either tumor-specific or 
genetically engineered are expanded ex vivo before being infused 
back into the patient. In this article, we will focus on genetically 
engineered T cells only.
Chimeric Antigen Receptors as Tool to 
Recognize Specific Tumor-Associated 
Antigens
As mentioned above, tumors are able to establish an immunosup-
pressive microenvironment resulting, amongst other effects, in 
the inhibition of an anti-tumor-specific T-cell response. This state 
is achieved through release of immunosuppressive cytokines, 
altered MHC expression, recruitment of regulatory T cells, and/
or the up-regulation of immune suppressing molecules such as 
CTLA-4, PD-1, and PD-L1 [reviewed in Ref. (195)]. Genetically 
engineered T cells, possessing a cloned tumor-specific TCR or 
chimeric antigen receptor (CAR) and thus the ability to recognize 
specific TAAs, might provide a new, promising immunothera-
peutic strategy for cancer treatment. CARs are constructed from 
an antigen-binding domain [i.e., single chain antibody variable 
fragment (scFv)] that is derived from the variable region (Fab-
fragment) of a mAb which is linked to a transmembrane motif 
as well as an intracellular signaling domain of one or more co-
stimulatory molecules such as CD28, Ox40, or CD137 (196).
Currently about 70 clinical trials investigating CAR T cell 
ITs are registered in ClinicalTrials.gov, with most of these stud-
ies exploring B-cell malignancies targeting CD19. One of these 
studies, a phase I trial of CD19-CAR T cells used in refractory 
B-cell malignancies, reported a CR in 70% of patients with acute 
lymphoblastic leukemia (B-ALL) as well as an OS at a median 
followup of 10 months with 51.6% at 9.7 months (197). A second 
study evaluating the effects of CD19-directed CAR (CTL019) 
T-cell therapy in relapsed or refractory ALL reported a 90% rate 
of complete remission (198). Along with other clinical trials (199, 
200), these findings suggest a high beneficial effect of adoptive cell 
transfer with anti-CD19 CAR T cells in patients suffering from 
B-cell malignancies with manageable toxicities. These results 
give rise for cautious optimism in the treatment of solid tumors, 
including advanced Her2-positive malignancies, GBM, neuro-
blastoma, sarcomas, melanoma, metastatic pancreatic cancer, and 
metastatic breast cancer. In order to enhance anti-tumor effects of 
CAR T cell therapy, it can also be combined with other therapy 
options or the so-called bi-specific CARs recognizing two anti-
gens that are composed of two tandem-scFv fragments separated 
by a linker (201). The lymphodepletive and tumoricidal effects of 
standard-of-care CT and RT might potentiate the expansion and 
function of adoptively transferred CAR T cells, as suggested by 
Riccione et al. (202). However, more data of combination of RT 
with CAR T cells are first needed to allow for definite conclusions 
whether this treatment induces enhanced anti-tumor responses, 
locally and systemically.
Summary
A tumor is much more than just an accumulation of tumor cells. 
The cell death resistance of the malignant cells to anti-cancer 
therapies is one massive problem in the clinic. One of the chal-
lenges for researchers and clinicians is to identify treatments that 
will overcome or bypass the cell death resistance mechanisms 
established by the tumor cells, but also those of the microenvi-
ronment (68). Nowadays, the involvement of the immune system 
as a vital player in the recognition and eradication of malignant 
cells is generally accepted (203). While RT and CT are crucial 
for curative and palliative treatments, they do not only display 
cytotoxic or cytostatic effects and target the tumor directly, but 
are also involved in the activation of the immune system through 
the induction of immunogenic cell death or immunostimulatory 
mechanisms (29). In general, the modulation of the immune 
system via modifications of either tumor or immune cells with 
methods such as mAbs or small molecule inhibitors provides 
a great potential in the improvement of cancer therapies and 
numerous pre-clinical and clinical studies are ongoing. Even 
though these approaches often induce only modest and transient 
clinical responses in distinct malignancies, a combination with 
RT, and/or immunogenic CT and additional immune therapies 
such as vaccination might result in an improved clinical benefit. 
Thus, additional multi-center large-scaled randomized stud-
ies further evaluating the safety, efficacy, and clinical local and 
systemic outcome of monotherapy and combinatorial strategies 
are urgently needed. A more personalized treatment of patients 
through integration of predictive and prognostic biomarkers and 
considering individual radiosensitivity together with time and 
dose adaptions should be in the mind of clinicians and scientist 
alike. However, both have to keep in mind: it is crucial to first 
gain knowledge about the mechanisms and mode of action of 
the treatments to then be able to design multimodal therapies 
with respect to combinations and chronology. And if it does not 
work in the first try, go back to the lab and find out what can be 
optimized.
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